



Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022

August 23, 2022

Webcast is Live at 12:30 p.m. ET

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 23, 2022-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation to the investment community at the Gilmartin Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 12:30 p.m. ET. A live audio webcast of the presentation will be available at the following link: <https://kvgo.com/corporate-services/surmodics-aug-2022>. Additionally, access the live audio webcast by navigating to the upcoming events under the investor relations portion of the Company's website at <https://surmodics.gcs-web.com/events-and-presentations> and clicking on the webcast icon. The webcast will be archived on the Company's website for 90 days following the live presentation.

About Surmodics, Inc.

Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission ("SEC").

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220823005085/en/): <https://www.businesswire.com/news/home/20220823005085/en/>

Tim Arens
952-500-7000
ir@surmodics.com

Source: Surmodics, Inc.